Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

J&J Loses Zytiga Patent Protection Ruling In Argentum Challenge

By Mike Botta | January 18, 2018

Argentum Pharmaceuticals wins patent invalidation trial against the sole remaining patent protecting Janssen’s Zytiga.

The U.S. Patent & Trademark Office (PTO) issued a final written decision Wednesday in Argentum Pharmaceuticals LLC’s inter partes review (IPR) against the sole unexpired patent covering Janssen Oncology, Inc.’s Zytiga (abiraterone acetate). Janssen Oncology is a subsidiary of Johnson & Johnson.  

Johnson & Johnson said it is evaluating its options concerning a possible rehearing request or appeal, according to a company statement.

Argentum had challenged all claims (1−20) of Janssen’s U.S. Patent No. 8,822,438, which the FDA’s Orange Book states will expire in August 24, 2027. 

In the decision, the PTO concluded that Argentum “satisfied its burden of demonstrating, by a preponderance of the evidence, that the subject matter of claims 1–20 would have been obvious,” and therefore ordered “that claims 1-20 are held unpatentable.“

“The inter partes review process is an important tool by which generic and biosimilar companies can create prescription drug savings by ensuring that non-innovative patents do not block competition,” Argentum’s CEO Jeffrey Gardner said following the decision. “Argentum’s core mission is to lower the cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.”  

Johnson & Johnson, meanwhile, issued the following statement: “We are disappointed in and strongly disagree with the U.S. Patent and Trademark Office’s (USPTO) decisions relating to Zytiga as part of the inter partes reviews. We are evaluating our options with respect to a request for rehearing and/or appeal to the Court of Appeals for the Federal Circuit. We believe the ‘438 patent is valid and will continue to vigorously defend it.”

But, Argentum’s Gardner expressed confidence that, if appealed, the decision would be upheld: “We believe that the PTO’s decision will be upheld if appealed by Janssen, and will save the U.S. healthcare system billions of dollars over the next decade. Those savings will inure to the benefit of American patients by improving their access to the high quality, safe, and effective FDA-approved generic alternatives that they deserve.”

Zytiga is used along with prednisone to treat men with prostate cancer that is resistant to medical or surgical treatments and that has spread to other parts of the body.

(Sources: Argentum Pharmaceuticals LLC via PR Newswire; Johnson & Johnson via PR Newswire)

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE